Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents

New England Journal of Medicine

Volumn 346, Issue 18, 2002, Pages 1357-1365

  Lowes, Brian D ^a   Gilbert, Edward M ^b   Abraham, William T ^a   Minobe, Wayne A ^a   Larrabee, Patti ^b   Ferguson, Debra ^a   Wolfel, Eugene E ^a   Lindenfeld, JoAnn ^a   Tsvetkova, Tatiana ^a   Robertson, Alastair D ^a   Quaife, Robert A ^a   Bristow, Michael R ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; METOPROLOL; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETIC REGULATION; HEART DILATATION; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE BIOPSY; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE REMODELING; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOISOTOPE VENTRICULOGRAPHY; RANDOMIZED CONTROLLED TRIAL; RECEPTOR DENSITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARCOPLASMIC RETICULUM;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; CALCIUM-TRANSPORTING ATPASES; CARBAZOLES; CARDIOMYOPATHY, DILATED; FEMALE; GENE EXPRESSION; HEMODYNAMIC PROCESSES; HUMANS; MALE; METOPROLOL; MIDDLE AGED; MYOCARDIUM; MYOSIN HEAVY CHAINS; PROPANOLAMINES; RECEPTORS, ADRENERGIC, BETA; RNA, MESSENGER; STROKE VOLUME; VENTRICULAR MYOSINS;

EID: 0037007679     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa012630     Document Type: Article

References (32)

1. Medical therapy can improve the biological properties of the chronically failing heart: A new era in the treatment of heart failure
2. Dilated cardiomyopathies
3. Why does the myocardium fail? Insights from basic science
4. Selective gene expression in failing human heart: Quantification of steady-state levels of messenger RNA in endomyocardial biopsies using the polymerase chain reaction
5. Reversible alterations in myocardial gene expression in a young man with dilated cardiomyopathy and hypothyroidism
6. Analysis of beta-adrenergic receptor mRNA levels in human ventricular biopsy specimens by quantitative polymerase chain reactions: Progressive reduction of beta 1-adrenergic receptor mRNA in heart failure
7. Changes in gene expression in the intact human heart: Downregularion of α-myosin heavy chain in hypertrophied, failing ventricular myocardium
8. β-adrenergic receptor blockade in chronic heart failure
9. Differential effects of β-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol
10. What type of β-blocker should be used to treat chronic heart failure?
11. Expression profiling in the intact failing human heart
12. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart
13. Effects of carvedilol on systolic and diastolic left ventricular performance in idiopathic dilated cardiomyopathy or ischemic cardiomyopathy
14. Effects of carvedilol on right ventricular function in chronic heart failure
15. Cardiac remodeling - Concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling
16. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease
17. Time course of improvement in left ventricular function, mass, and geometry in patients with congestive heart failure treated with β-adrenergic blockade
18. Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure
19. Dose-response of chronic β-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy
20. Can response to β-blocker therapy in idiopathic dilated cardiomyopathy be predicted by baseline parameters?
21. β-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy
22. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure
23. Comparative efficacy of three indexes of left ventricular performance derived from pressure-volume loops in heart failure induced by tachypacing
24. Management of heart failure
25. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure
26. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure
27. Mechanism of action of beta-blocking agents in heart failure
28. Measurement of right ventricular function
29. The molecular biology of heart failure
30. Molecular and cellular mechanisms of myocardial failure
31. Long-term beta adrenoceptor-mediated alteration in contractility and expression of phospholamban and sarcoplasmic reticulum Ca++-ATPase in mammalian ventricle
32. Isoproterenol infusion induces alterations in expression of hypertrophy-associated genes in rat heart